Immucell (ICCC) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $7.2M
- Gross margin
- 40.32%
- Net income (trailing twelve months)
- $787,373.00
- Net income (quarter)
- $1.8M
- Net margin
- 2.57%
- Return on equity
- 2.57%
- Book value per share
- $3.45
- Price to book
- 3.07
- Debt to assets
- 32.72%
Company profile
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Frequently asked questions
Is Immucell (ICCC) profitable?
Yes. Immucell earned $787,373.00 in net income over the trailing twelve months, a net margin of 2.57%.
How much revenue does Immucell (ICCC) make?
Immucell generated $30.7M in revenue over the trailing twelve months, up 11.50% year over year.
What is ICCC's P/E ratio?
Immucell trades at 122.4 times trailing twelve-month earnings, on an EPS of $0.08.
How do I buy stock in Immucell (ICCC)?
ICCC trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.
